Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer

J Clin Oncol. 2020 Aug 10;38(23):2699-2700. doi: 10.1200/JCO.20.00789. Epub 2020 Jun 9.

Authors

Shigemasa Takamizawa¹, Hiroto Ishiki¹, Tatsunori Shimoi¹, Masaki Shimizu¹, Eriko Satomi¹

Affiliation

¹ Shigemasa Takamizawa, MD, and Hiroto Ishiki, MD, Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan; Tatsunori Shimoi, MD, PhD, Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; and Masaki Shimizu, MD, and Eriko Satomi, MD, Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.

PMID: 32516091
DOI: 10.1200/JCO.20.00789

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Cisplatin*
Cyclophosphamide
Doxorubicin
Germ Cells
Humans
Neoadjuvant Therapy

Substances

Doxorubicin
Cyclophosphamide
Cisplatin

Associated data

ClinicalTrials.gov/NCT01670500